Avances en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular

Mokdad, 2000, Diabetes trends in the U.S.: 1990-1998, Diabetes Care, 23, 1278, 10.2337/diacare.23.9.1278 King, 1998, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 Mokdad, 2000, The continuing epidemic of obesity in the United States, JAMA, 284, 1650, 10.1001/jama.284.13.1650 Ogden, 2006, Prevalence of overweight and obesity in the United States, 1999-2004, JAMA, 295, 1549, 10.1001/jama.295.13.1549 World Health Organization. Obesity: preventing and managing the global epidemic: report of a WHO consultattion. 2000. Klein, 2004, Circulation, 110, 2952, 10.1161/01.CIR.0000145546.97738.1E Eckel, 2005, The metabolic syndrome, Lancet, 365, 1415, 10.1016/S0140-6736(05)66378-7 National Institute of Diabetes and Digestive and Kidney Diseases National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States, 2005. Bethesda, MD: U.S. Department of Health and Human Services, National Institute of Health, 2005. Rosamond, 2006, Heart Disease and Stroke Statistics—2007 Update. A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, Circulation, 115, e69 Ford, 2002, Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey, JAMA, 287, 356, 10.1001/jama.287.3.356 Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific statement: executive summary, Circulation, 112, e285 Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diabetes Care, 24, 683, 10.2337/diacare.24.4.683 Elrick, 1964, Plasma insulin response to oral and intravenous glucose administration, J Clin Endocrinol Metab, 24, 1076, 10.1210/jcem-24-10-1076 Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology, 136, 3585, 10.1210/endo.136.8.7628397 Qualmann, 1995, Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose), Scand J Gastroenterol, 30, 892, 10.3109/00365529509101597 Nauck, 1997, Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans, Am J Physiol, 273, E981 Flint, 1998, Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans, J Clin Invest, 101, 515, 10.1172/JCI990 Kreymann, 1987, Glucagonlike peptide-1 7-36: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 Drucker, 2006, The biology of incretin hormones, Cell Metab, 3, 153, 10.1016/j.cmet.2006.01.004 Egan, 2003, GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells, Diabetes Metab Res Rev, 19, 115, 10.1002/dmrr.357 Meier, 2005, Glucagon-like peptide 1(GLP-1) in biology and pathology, Diabetes Metab Res Rev, 21, 91, 10.1002/dmrr.538 Li, 2003, Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis, J Biol Chem, 278, 471, 10.1074/jbc.M209423200 Farilla, 2003, Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets, Endocrinology, 144, 5149, 10.1210/en.2003-0323 Holst, 2004, The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism, Diabetes, 53, S197, 10.2337/diabetes.53.suppl_3.S197 Nauck, 2004, Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes, Horm Metab Res, 36, 852, 10.1055/s-2004-826175 Nauck, 2005, Glucagon-like peptide 1 and its derivatives in the treatment of diabetes, Regul Pept, 128, 135, 10.1016/j.regpep.2004.07.014 Gutzwiller, 1999, Glucagon-like peptide-1: a potent regulator of food intake in humans, Gut, 44, 81, 10.1136/gut.44.1.81 Naslund, 1998, Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men, Am J Clin Nutr, 68, 525, 10.1093/ajcn/68.3.525 Donahey, 1998, Intraventricular GLP-1 reduces short- but not long-term food intake or body weight in lean and obese rats, Brain Res, 779, 75, 10.1016/S0006-8993(97)01057-3 Verdich, 2001, A meta-analysis of the effect of glucagonlike peptide-1 (7-36) amide on ad libitum energy intake in humans, J Clin Endocrinol Metab, 86, 4382 Meeran, 1999, Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat, Endocrinology, 140, 244, 10.1210/endo.140.1.6421 Brenner, 2003, Restoration of first-phase insulin secretion by the imidazoline compound LY374284 in pancreatic islets of diabetic db/db mice, Ann N Y Acad Sci, 1009, 332, 10.1196/annals.1304.042 Meier, 2003, Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes, J Clin Endocrinol Metab, 88, 2719, 10.1210/jc.2003-030049 Nauck, 2002, Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers, J Clin Endocrinol Metab, 87, 1239, 10.1210/jcem.87.3.8355 Holst, 2004, On the Physiology of GIP and GLP-1, Horm Metab Res, 36, 747, 10.1055/s-2004-826158 Toft-Nielsen, 2001, Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients, J Clin Endocrinol Metab, 86, 3717, 10.1210/jcem.86.8.7750 Nauck, 1993, Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 36, 741, 10.1007/BF00401145 Zander, 2002, Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study, Lancet, 359, 824, 10.1016/S0140-6736(02)07952-7 Eng, 1992, Isolation and characterization of exendin-4, an exendin-3 analogue, fromHeloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas, J Biol Chem, 267, 7402, 10.1016/S0021-9258(18)42531-8 Young, 1999, Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta), Diabetes, 48, 1026, 10.2337/diabetes.48.5.1026 Parkes, 2001, Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro, Metabolism, 50, 583, 10.1053/meta.2001.22519 Edwards, 2001, Exendin -4 reduces fasting and post-mordial glucose and decreases energy intake in healthy volunteers, Am J Physiol Endocrinol Metabol, 281, E155, 10.1152/ajpendo.2001.281.1.E155 Kolterman, 2003, Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes, J Clin Endocrinol Metab, 88, 3082, 10.1210/jc.2002-021545 Strader, 2005, Gastrointestinal hormones and food intake, Gastroenterology, 128, 175, 10.1053/j.gastro.2004.10.043 Joy, 2005, Incretin mimetics as emerging treatments for type 2 diabetes, Ann Pharmacother, 39, 110, 10.1345/aph.1E245 Fineman, 2003, Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes, Diabetes Care, 26, 2370, 10.2337/diacare.26.8.2370 Buse, 2004, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes, Diabetes Care, 27, 2628, 10.2337/diacare.27.11.2628 DeFronzo, 2005, Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 28, 1092, 10.2337/diacare.28.5.1092 Kendall, 2005, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care, 28, 1083, 10.2337/diacare.28.5.1083 Zinman, 2006, Safety and efficacy of exenatide in patients with type 2 diabetes mellitus using thiazolidenediones with or without metformin, Diabetes, 55, A28 Riddle, 2006, Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin, Diabetes Metab Res Rev, 22, 483, 10.1002/dmrr.646 Bjerre, 2001, GLP-1 derivatives as novel compounds for the treatment of diabetes: selection of NN2211 for clinical development, Drugs Future, 26, 677, 10.1358/dof.2001.026.07.628723 Bjerre, 2003, Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacy, Diabetes, 52, 321 Nauck, 2006, Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes, Exp Clin Endocrinol Diabetes, 114, 417, 10.1055/s-2006-924230 Vilsboll, 2006, Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes, Diabetes, 55, A27 Saad, 2002, The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with type 2 diabetes, Diabetologia, 45, 44 Madsbad, 2004, Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial, Diabetes Care, 27, 1335, 10.2337/diacare.27.6.1335 Kim, 2006, Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes, Diabetes, 55, 116. Mentlein, 1999, Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides, Regul Pept, 85, 9, 10.1016/S0167-0115(99)00089-0 Kieffer, 1995, Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV, Endocrinology, 136, 3585, 10.1210/endo.136.8.7628397 Vilsboll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 McIntosh, 2005, Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?, Regul Pept, 128, 159, 10.1016/j.regpep.2004.06.001 Marguet, 2000, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proc Natl Acad Sci USA, 97, 6874, 10.1073/pnas.120069197 Mitani, 2002, Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity, Jpn J Pharmacol, 88, 442, 10.1254/jjp.88.442 Herman, 2005, Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clin Pharmacol Ther, 78, 675, 10.1016/j.clpt.2005.09.002 Ahren, 2004, Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes, J Clin Endocrinol Metab, 89, 2078, 10.1210/jc.2003-031907 Mentlein, 2005, Therapeutic assessment of glucagon-like peptide-1 agonists compared with dipeptidyl peptidase IV inhibitors as potential antidiabetic drugs, Expert Opin Investig Drugs, 14, 57, 10.1517/13543784.14.1.57 Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 Charbonnel, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesinadequately controlled with metformin alone, Diabetes Care, 29, 2638, 10.2337/dc06-0706 Ahren, 2004, Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes, Diabetes Care, 27, 2874, 10.2337/diacare.27.12.2874 Pi-Sunyer, 2007, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes, Diabetes Res Clin Pract, 76, 132, 10.1016/j.diabres.2006.12.009 Rosenstock, 2007, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial, Diabetes Care, 30, 217, 10.2337/dc06-1815 Nauck, 2005, The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1, Diabetologia, 48, 608, 10.1007/s00125-005-1704-8 Holst, 2004, Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors, Expert Opin Emerg Drugs, 9, 155, 10.1517/14728214.9.1.155 Holst, 2005, Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors, Diabetologia, 48, 612, 10.1007/s00125-005-1705-7 Deacon, 2002, Preservationof active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs, J Endocrinol, 172, 355, 10.1677/joe.0.1720355 Mest, 2005, Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes, Diabetologia, 48, 616, 10.1007/s00125-005-1707-5 Gorrell, 2001, CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes, Scand J Immunol, 54, 249, 10.1046/j.1365-3083.2001.00984.x Lambeir, 2003, Exploration of the active site of dipeptidyl peptidase IV from Porphyromonas gingivalis. Comparison with the human enzyme, Adv Exp Med Biol, 524, 29, 10.1007/0-306-47920-6_3 Demuth, 2005, Type 2 diabetes—therapy with dipeptidyl peptidase IV inhibitors, Biochim Biophys Acta, 1751, 33, 10.1016/j.bbapap.2005.05.010 Howlett, 2004, Cannabinoid physiology and pharmacology: 30 years of progress, Neuropharmacology, 47, 345, 10.1016/j.neuropharm.2004.07.030 Bensaid, 2003, The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells, Mol Pharmacol, 63, 908, 10.1124/mol.63.4.908 Osei-Hyiaman, 2005, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity, J Clin Invest, 115, 1298, 10.1172/JCI200523057 Juan-Pico, 2006, Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell, Cell Calcium, 39, 155, 10.1016/j.ceca.2005.10.005 DiMarzo, 2004, The endocannabinoid system and its therapeutic exploitation, Nat Rev Drug Discov, 3, 771, 10.1038/nrd1495 Pacher, 2006, The endocannabinoid system as an emerging target of pharmacotherapy, Pharmacol Rev, 58, 389, 10.1124/pr.58.3.2 Schlicker, 2001, Modulation of transmitter release via presynaptic cannabinoid receptors, Trends Pharmacol Sci, 22, 565, 10.1016/S0165-6147(00)01805-8 Vaughan, 2005, Retrograde signalling by endocannabinoids, Handb Exp Pharmacol, 367, 10.1007/3-540-26573-2_12 Colombo, 1998, Appetite suppression and weight loss after the cannabinoid antagonist SR 141716, Life Sci, 63, L113, 10.1016/S0024-3205(98)00322-1 Vickers, 2003, Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats, Psychopharmacology (Berl), 167, 103, 10.1007/s00213-002-1384-8 Kirkham, 2005, Endocannabinoids in the regulation of appetite and body weight, Behav Pharmacol, 16, 297, 10.1097/00008877-200509000-00004 Pi-Sunyer, 2006, Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial, JAMA, 295, 761, 10.1001/jama.295.7.761 van Gaal, 2005, Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study, Lancet, 365, 1389, 10.1016/S0140-6736(05)66374-X Despres, 2005, Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia, N Engl J Med, 353, 2121, 10.1056/NEJMoa044537 Scheen, 2006, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study, Lancet, 368, 1660, 10.1016/S0140-6736(06)69571-8 Scheen, 2006, Rimonabant improves cardiometabolic risk profile in obese or overweight subjects: overview of RIO studies, Rev Med Suisse, 2, 1916 Zigmond, 1983, The hospital anxiety and depression scale, Acta Psychiatr Scand, 67, 361, 10.1111/j.1600-0447.1983.tb09716.x Brazier, 2004, Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D, Value Health, 7, 490, 10.1111/j.1524-4733.2004.74012.x Pagotto, 2006, The emerging role of the endocannabinoid system in endocrine regulation and energy balance, Endocr Rev, 27, 73, 10.1210/er.2005-0009